Correction to: J Exp Clin Cancer Res (2019) 38:199

https://doi.org/10.1186/s13046-019-1208-x

In the original publication of this article [1], there is a mistake in Fig. 4e.

The corrected Fig. 4e should be:

Fig. 1
figure 1

Upregulation of ST6GAL1 promotes proliferation and chemoresistance in T-ALL cell lines (a) qRT-PCR and western blot were carried out to detect ST6GAL1 levels. b The expression of FITC-SNA was dertermined. c The viability of cells transfected with ST6GAL1 was determined by CCK8 assay at 0, 24, 48, 72 and 96 h. d Enhanced ST6GAL1 facilitated colony formation. e Ki67 expression was observed by immunoflourescence, red fluorescence: Ki67, blue fluorescence: DAPI. f CCK8 assays were used to measure the resistance to ADR, VCR and Pacliatxel. The absorbance was measured at 450 nm. g The IC50 values were calculated. h Relative molecular expression of key caspase-dependent apoptosis was analyzed by western blot. i The apoptosis rate of different treated cells was analyzed by FCM. ST6GAL1 upregulation inhibited cells survival in response to ADR. j Effects of ST6GAL1 upregulation on tumor growth were shown in vivo. k ST6GAL1 and Ki67 expression was observed by IHC staining. Data were means ± SD of triplicate determinants (*P < 0.05)